ex scientia Ltd

Activities: Research & Development

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

Transatlantic partnership to screen 15,000 drugs for COVID-19 treatments

Exscientia has announced a joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research 
Research & Development

Exscientia initiates sixth AI drug discovery partnership

Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Analysis

Exscientia appoints Georgy Egorov as Chief Financial Officer
Research & Development

Elsevier welcomes six biotech and pharma start-ups to The Hive

Start-ups working on a range of technologies and discoveries — from AI to immunotherapy — receive complimentary access to Elsevier's information solutions to accelerate innovation
Recruitment

Exscientia appoints Alex Snow as Deputy Chairman

Digital

Exscientia enters drug discovery collaboration with GSK

Exscientia, an innovative artificial intelligence driven drug discovery company, has entered into a strategic drug discovery collaboration with GlaxoSmithKline
Research & Development

Collaboration in bispecific-small-molecule drugs for metabolic disease

€250m agreement between Exscientia and Sanofi is for multiple-product development and licence option
Subscribe now